Drug Type Small molecule drug |
Synonyms THU, NSC-112907 |
Target |
Mechanism CDA inhibitors(Cytidine deaminase inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC9H16N2O6 |
InChIKeyUCKYOOZPSJFJIZ-XVKVHKPRSA-N |
CAS Registry18771-50-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Carcinoma | Phase 2 | US | 11 Apr 2018 | |
Esophageal Carcinoma | Phase 2 | US | 11 Apr 2018 | |
Malignant Pleural Mesothelioma | Phase 2 | US | 11 Apr 2018 | |
metastatic non-small cell lung cancer | Phase 2 | US | 11 Apr 2018 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 06 Jun 2017 | |
Bladder Cancer | Phase 2 | US | 20 Aug 2009 | |
Breast Cancer | Phase 2 | US | 20 Aug 2009 | |
Head and Neck Neoplasms | Phase 2 | US | 20 Aug 2009 | |
Lung Cancer | Phase 2 | US | 20 Aug 2009 | |
Acute Myeloid Leukemia | Phase 2 | - | - |
Phase 2 | 13 | (Nivolumab) | whexaubuzv(rtrzuvgevv): P-Value = 0.05 View more | - | 10 Dec 2020 | ||
(Oral THU/Decitabine + Nivolumab) | |||||||
Early Phase 1 | 5 | Positron emission tomography (PET)/Computed tomography (CT)+Tetrahydrouridine intravenous (IV)+[F-18]-5-FLUORO-2'-DEOXYCYTIDINE | rnlsrrovzn(qlgswnxyvg) = jhnknrupnb dntmvfrkdj (dvpyivfbon, aafdcjcwaz - xmznyzvool) View more | - | 22 May 2020 | ||
Phase 2 | 95 | hcvfznpjjq(ivbibistet) = modimijezo yzyuqipcyp (wctvijjhlk, cfwznberub - qpjgsbmcbl) View more | - | 27 Dec 2019 | |||
Phase 1 | 25 | qavuwbhqec(gftcjlkltu) = pjoslhsmpn lzqoimhfle (ajduojazri ) View more | - | 01 Sep 2017 | |||
Phase 1 | - | tetrahydrouridine+FdCyd | etabnfapsd(jxdnzmbffr) = 100 mg/m2/day FdCyd with 350 mg/m2/day THU pcokycztyy (fgutbkigau ) View more | Positive | 01 Mar 2015 |